This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hyperfine (HYPR) delivered earnings and revenue surprises of 0% and 15.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Hyperfine's (HYPR) Swoop System Gets New FDA-Cleared Software
by Zacks Equity Research
Hyperfine (HYPR) announces the receipt of FDA clearance for its ninth-generation AI-powered Swoop system software.
Hyperfine (HYPR) to Release ACTION PMR Study Data for Swoop
by Zacks Equity Research
Hyperfine (HYPR) is set to release study data in August 2024, showing the value of the Swoop system in enabling critical stroke treatment choices in urgent care settings.
Hyperfine (HYPR) Inks New Partnerships to Expand in Europe
by Zacks Equity Research
Hyperfine (HYPR) announces that it has signed agreements with experienced and accomplished distributors in Germany, Austria, Switzerland, and key Nordic markets for its Swoop, a portable MRI system.
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These are Vita Coco Company (COCO), AMC Entertainment (AMC), Hyperfine (HYPR), Aptevo Therapeutics (APVO) and CLEAR Secure (YOU).
Hyperfine, Inc. (HYPR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hyperfine (HYPR) delivered earnings and revenue surprises of 0% and 8.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Hyperfine, Inc. (HYPR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Hyperfine (HYPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down -19% in 4 Weeks, Here's Why Hyperfine (HYPR) Looks Ripe for a Turnaround
by Zacks Equity Research
Hyperfine (HYPR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Hyperfine, Inc. (HYPR) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Hyperfine (HYPR) delivered earnings and revenue surprises of 11.76% and 26.61%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 37.14% and 0.27%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 26.92% and 2.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Hyperfine (HYPR) Progresses in MRI Space With Latest FDA Nod
by Zacks Equity Research
Hyperfine's (HYPR) updated Swoop software is expected to make brain imaging more accessible and clinically relevant.
Down -21.28% in 4 Weeks, Here's Why Hyperfine, Inc. (HYPR) Looks Ripe for a Turnaround
by Zacks Equity Research
Hyperfine, Inc. (HYPR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -15.07% in 4 Weeks, Here's Why You Should You Buy the Dip in Hyperfine, Inc. (HYPR)
by Zacks Equity Research
Hyperfine, Inc. (HYPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Hyperfine, Inc. (HYPR) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Hyperfine, Inc. (HYPR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Hyperfine, Inc. (HYPR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Hyperfine, Inc. (HYPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -57.33% and 26.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of -61.11% and 0.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 16.13% and 2.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Silk Road Medical (SILK) delivered earnings and revenue surprises of 10.26% and 4.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Hyperfine (HYPR) ACTION PMR Study Targets Better Stroke Care
by Zacks Equity Research
Hyperfine's (HYPR) ACTION PMR study focuses on utilizing point-of-care brain imaging to identify strokes and salvageable brain tissue.
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 33.33% and 2.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Tactile Systems Technology (TCMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tactile Systems Technology (TCMD) delivered earnings and revenue surprises of 88.89% and 8.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -12.50% and 1.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Take the Zacks Approach to Beat the Market: Microsoft, Novo Nordisk, General Mills in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.